Melphalan modulates the expression of E7-specific biomarkers in E7-Tg mice

Area of Science:

• Oncology
• Molecular Biology
• Carcinogenesis Research

Background:

• Human papillomavirus (HPV) oncoproteins, like E7, drive oncogenesis by interacting with tumor suppressors such as Rb.
• E7 oncoprotein biomarkers were previously identified in E7-transgenic (Tg) mice, establishing a model for HPV-related cancer research.

Purpose of the Study:

• To investigate if a genotoxic carcinogen, melphalan, modulates carcinogenesis in E7-Tg mice.
• To analyze the effects of melphalan on E7-specific gene and protein expression in lung tissues.

Main Methods:

• E7-Tg mice were intraperitoneally injected with melphalan for eight weeks at two-day intervals.
• Gene and protein expression analysis was performed using Omics approaches and quantitative real-time PCR (RT-qPCR).
• RT-qPCR was specifically used to confirm modulation of E7 biomarkers by melphalan treatment.

Main Results:

• Melphalan treatment resulted in the down-regulation of previously up-regulated E7 markers, including cyclin B1, CD166, and actin alpha1.
• Expression of previously down-regulated E7 marker vimentin was restored following melphalan treatment.
• These modulations indicate a significant impact of melphalan on E7-specific molecular pathways.

Conclusions:

• Melphalan demonstrates potential in inhibiting carcinogenesis.
• The mechanism of inhibition appears to involve the modulation of E7-specific genes and proteins in lung tissues of E7-Tg mice.
• These findings suggest melphalan as a potential therapeutic agent for HPV-associated cancers.